ESC Professional Premium Access

Dual pathway inhibitor therapy switched from dual antiplatelet therapy reduces risk of recurrent in-stent occlusion after endovascular therapy for femoropopliteal in-stent occlusion.

Congress Presentation

About the speaker

Mr Sho Nakao

Kansai Rosai Hospital, Amagasaki (Japan)
0 follower

8 more presentations in this session

Reduction in the risk of major adverse limb events with ezetimibe versus placebo in addition to statin therapy: insights from the IMPROVE IT trial

Speaker: Doctor M. Bonaca (Aurora, US)

Thumbnail

Lipoprotein(a) and the risk of major adverse limb events in patients with stable atherosclerotic vascular disease

Speaker: Doctor M. Bonaca (Aurora, US)

Thumbnail

The impact of Covid-19 on mortality and clinical characteristics in hospitalized patients with peripheral artery disease in the year 2020

Speaker: Professor C. Hehrlein (Freiburg, DE)

Thumbnail

Association between electronic nicotine delivery systems use and risk of stroke: A systematic review and meta-analysis of observational studies with 822,162 participants.

Speaker: Professor M. Banach (Lodz, PL)

Thumbnail

Olive extract enriched with hydroxytyrosol improves cardiac and vascular function in patients with stable coronary artery disease: a double-blind, placebo-controlled trial.

Speaker: Doctor I. Ikonomidis (Athens, GR)

Thumbnail

Access the full session

Arterial occlusive disease: a chronic pandemic needing attention to detail

Speakers: Mr S. Nakao, Doctor M. Bonaca, Doctor M. Bonaca, Professor C. Hehrlein, Professor M. Banach...
Thumbnail

About the event

Image

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations